You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復旦張江(01349.HK)用於治療晚期實體瘤藥物獲藥監局受理臨床試驗申請
復旦張江(01349.HK)公布,收到國家藥監局核准簽發的《受理通知書》,注射用FZ-AD005抗體偶聯劑(即抗DLL3抗體偶聯BB05)用於治療晚期實體瘤的藥物I期臨床試驗申請獲得受理。 據公開資料顯示,該藥物是目前首個DLL3靶點的拓撲異構(酉每)抑制劑類ADC藥物,其可通過與DLL3陽性的腫瘤細胞結合並內吞,在溶(酉每)體內通過蛋白(酉每)剪切定向釋放小分子細胞毒藥物(拓撲異構(酉每)I抑制劑),殺傷腫瘤細胞。該藥物擬用於治療晚期實體瘤,包括但不限於小細胞肺癌、大細胞神經內分泌癌、前列腺癌等。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account